Reported Q: Q1 2025 Rev YoY: N/A EPS YoY: -640,924.5% Move: +13.60%
Propanc Biopharma Inc
PPCBD
$5.68 13.60%
Exchange PNK Sector Healthcare Industry Biotechnology
Q1 2025
Published: Nov 14, 2024

Company Status Snapshot

Fast view of the latest quarter outcome for PPCBD

Reported

Report Date

Nov 14, 2024

Quarter Q1 2025

Revenue

N/A

YoY: N/A

EPS

-287.82

YoY: -640,924.5%

Market Move

+13.60%

Previous quarter: Q4 2024

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

  • EPS of $-287.82 decreased by 640% from previous year
  • Net income of -354.31K
  • "Not available" - Management
PPCBD
Company PPCBD

Executive Summary

Propanc Biopharma reported a results quarter (QQ1 2025) with no revenue and a material net loss, underscoring a highly cash-burn business model typical of early-stage biotech companies. Operating losses were driven primarily by substantial SG&A and R&D expenses in the context of negligible topline generation. For QQ1 2025, the company posted: net income of -$354,310 and an operating loss of -$290,790, with EBITDA of -$262,547. Operating cash flow was -$235,515 and free cash flow was also -$235,515, highlighting a weak cash runway. The balance sheet shows an extremely leveraged and fragile position: total liabilities of $4.17 million versus total assets of only $63,644 and negative stockholders’ equity of -$4.11 million. Cash at end of period stood at $9,268, with net debt of approximately $1.094 million. Liquidity ratios are profoundly stressed (current ratio 0.00525; cash ratio 0.00226), signaling an acute going-concern risk absent new funding or monetization of a partnership/licensing deal.

Given the preclinical nature of Propanc’s lead programs (PRP and POP1) and the absence of reported revenue or meaningful near-term commercial milestones, the investment thesis remains highly speculative. Short-term catalysts would hinge on financing activities (equity/convertible funding or strategic partnerships) or tangible pipeline progress (IND filings or meaningful preclinical readouts). Absent such catalysts, the stock trades with a high probability of further dilution and continued negative earnings trajectory. Investors should closely monitor any announced financing plans, collaboration updates, or clinical milestones that could materially alter the company’s liquidity profile or optionality in its pipeline.

Key Performance Indicators

Operating Income
Increasing
-290.79K
QoQ: -11.89% | YoY: 30.27%
Net Income
Decreasing
-354.31K
QoQ: 1.19% | YoY: -0.94%
EPS
Decreasing
-287.82
QoQ: -199.97% | YoY: -640 924.50%

Revenue Trend

Margin Analysis

Historical Earnings Comparison

PeriodRevenue ($M)EPS ($)YoY GrowthReport
Q3 2025 0.00 -12.50 +0.0% View
Q2 2025 0.00 -32.23 +0.0% View
Q1 2025 0.00 -287.82 +0.0% View
Q4 2024 0.00 -95.95 +0.0% View
Q3 2024 0.00 -296.77 +0.0% View